Clinical Professor of Medicine, UCLA
Rheumatology
Dr. Robin K. Dore works in the field of Rheumatology. He attended University of California Irvine School of Medicine. University of California Irvine School of Medicine has a rank of 45 in research and a 62 in primary care He has 12 awards "Top Doctors:LA Area", "Top Doctors:San Diego Area", "Top Doctors:Southern California", "CMS Meaningful Use Stage 1 Certification", "Distinguished Teaching Award", "Marilyn Magram Award for Excellence in Community and Professional Education", "Jane Wyman Humanitarian Award", "Distinguished Service Award", "Most Compassionate Doctor", "Fellow (FACR)", "Super Doctor" and "Top MD". Robin K. Dore is a published doctor. He has 25 papers published. The most current publication "Efficacy and safety of etodolac and naproxen in patients with osteoarthritis of the knee: a double-blind, placebo-controlled study." Robin Dore accepts all Medicare patients.
Publications
- Data from Extension Trials: Denosumab and Zoledronic Acid.
- The RANKL Pathway and Denosumab.
- How to prevent glucocorticoid-induced Osteoporosis.
- Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid Arthritis receiving concurrent glucocorticoids or bisphosphonates.
- Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid Arthritis patients.
- Patient experience with a new teriparatide delivery device.
- Gout: what primary care physicians want to know.
- The Gout diagnosis.
- Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid Arthritis: a twelve-month, multicenter, randomized, double-bli...
- Gastrointestinal tolerability of etoricoxib in rheumatoid Arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiv...
- The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid Arthritis.
- Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis.
- Reduced risk of back pain following teriparatide treatment: a meta-analysis.
- Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients w...
- A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with os...
- Osteoporosis in the elderly: a clinical perspective of current and future therapies.
- Cevimeline for the treatment of xerostomia in patients with Sjögren Syndrome: a randomized trial.
- Efficacy and safety of etodolac and naproxen in patients with osteoArthritis of the knee: a double-blind, placebo-controlled study.
- [A comparison between quantitative computed tomography and dual-energy densitometry in the study of patients at risk for postmenopausal Osteoporosis].
- The present and future adequacy of rheumatology manpower. A study of health care needs and physician supply.
- [Computerized tomography in surgically treated lumbar disk hernia. Multicenter study].
- [Quantitative computerized tomography of the vertebral spongiosa. Proposal of a method applicable to the study of postmenopausal Osteoporosis].
- Clinical utility of etanercept in the treatment of arthritides in children and adolescents.
- Long-term safety, efficacy, and patient acceptability of teriparatide in the management of glucocorticoid-induced Osteoporosis.
Schools
University Of California Irvine College Of Medicine
La Cnty Harbor University Ca La Med Center
Pomona College Claremont Ca
Procedures Preformed
- Bone Density Scan
- Joint Drainage
- Joint Injection
- Myofascial Trigger Point Injection
- View All
Conditions Treated
- Ankylosing Spondylitis
- Arthritis
- Calcium Pyrophosphate Dihydrate Deposition Disease (CPPD)
- Fibromyalgia
- View All
Doctors Specialties
Accepted Insurances
- HealthKeepers Plus POS
- Medicare MCR
Awards
- Top Doctors:LA Area
- Top Doctors:San Diego Area
- Top Doctors:Southern California
- CMS Meaningful Use Stage 1 Certification
- Distinguished Teaching Award
- Marilyn Magram Award for Excellence in Community and Professional Education
- Jane Wyman Humanitarian Award
- Distinguished Service Award
- Most Compassionate Doctor
- Fellow (FACR)
- Super Doctor
- Top MD
Education
-
UCLA Medical Center
-
University of California Irvine School of Medicine
Hospital
-
St. Joseph Hospital
Drug Facts
| NPI NUMBER |
|
1619972510 |
| NPPES Provider LastName |
|
DORE |
| NPPES Provider FirstName |
|
ROBIN |
| NPPES Provider ZIPCode |
|
927802751 |
| NPPES Provider State |
|
CA |
| Specialty Description |
|
Rheumatology |
| Total Claim Count |
|
8402.0 |
| Distinct Opioid Count |
|
6.0 |
| Opioid Claim Count |
|
750.0 |
| Percent Opioid Claims |
|
8.93 |
Helpful Reviews
Give
Anonymous Review
Medicare Facts
| National Provider Identifier [NPI] |
1619972510 |
| Last Name Of The Provider |
DORE |
| First Name Of The Provider |
ROBIN |
| View All |
|
Similar Doctors
Doctor Directory | TOS | twitter | FB | Angel | blog
This Doctor is OpenDoctor Recommended.